GSK: ABL Bio lands $2.8 licensing agreement with GSK

ABL Bio Inc. announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases. ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected to fetch up to 2.1 billion p...